Company intelligence / Profile preview

Vascular Pharmaceuticals, Inc.

Chapel Hill, North Carolina, United Statesvascularpharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

VPI-2960B is currently in Phase 2 clinical trials. Studies in animal models have shown that it may stop and even reverse the progression of diabetic nephropathy.

Therapeutic areas: EndocrinologyNephrology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

VPI-2690B

Partnerships

Janssen Biotech, Inc.

Beyond the preview

Go deeper on Vascular Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vascular Pharmaceuticals, Inc..

Explore the full profile